看见一个 Expert Review of Anticancer Therapy。你们前面用依维莫斯，血、肝肾功能还好。下一步是否考虑索拉非尼+依维莫斯。供你参考。& i; f2 w7 y( z" o# E% j
" ^0 G! r9 m7 x( N, h/ ^
) }: S0 x: y6 B' t: O. r" q
Currently available feasibility data for possible combination strategies.
& p; t, i0 [ R' ]+ L————————————————————————————————
+ n: f5 q8 f/ W9 sCombination Feasibility according to preliminary data 6 B! H' d8 D* ^2 X- i. y, M
——————————————————————————————————
& @0 A$ s! o0 s; M H. `" rBevacizumab + sorafenib Yes, reduced dose 6 q) ^& N" v+ W. N4 ?& T$ R
Bevacizumab + sunitinib† No
5 i W4 _" C5 \7 Z3 V, Z) PBevacizumab + temsirolimus Yes
/ _2 q: \" A8 y$ s" {0 ~, R2 `Bevacizumab + everolimus Yes , B( h4 c+ ? T
Sorafenib + sunitinib ? ' g# h% I5 `6 L) S: y
Sorafenib + temsirolimus Yes, reduced dose 1 U( q. l) s7 I
Sorafenib + everolimus Yes, reduced dose
( e' y# O9 X2 D4 u4 x* kSunitinib + temsirolimus† No , w: L N- Z# f# J6 i9 ?
Sunitinib + everolimus ?
- J& [4 H: F+ _+ q. `. z/ ETemsirolimus + everolimus ?
! u" ]! W' E2 z) E3 r1 S& ?———————————————————— u' M6 R, Y$ {& r1 Y
†Led to US FDA warning.
; y9 b0 N; r) |7 x: n?: As yet unattempted combination.
! \5 B8 {) n( P* L/ ]3 J% r |
显身卡
